# OP \$280,00 1190280

# PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

# **CONVEYING PARTY DATA**

Name	Execution Date
INNOGENETICS N.V.	03/20/2008

### **RECEIVING PARTY DATA**

Name:	GENimmune
Street Address:	Technologiepark 6
City:	Ghent
State/Country:	BELGIUM
Postal Code:	B-9052

### PROPERTY NUMBERS Total: 7

Property Type	Number
Application Number:	11902807
Application Number:	11381408
Patent Number:	6613333
Patent Number:	6555114
Patent Number:	6689368
Patent Number:	7101561
Patent Number:	7314925

# CORRESPONDENCE DATA

Fax Number: (703)816-4100

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 703-816-4000 Email: pp@nixonvan.com

Correspondent Name: NIXON & VANDERHYE, PC

Address Line 1: 901 NORTH GLEBE ROAD, 11TH FLOOR

Address Line 4: ARLINGTON, VIRGINIA 22203

ATTORNEY DOCKET NUMBER: BJS-2551-217

PATENT

500506996 REEL: 020762 FRAME: 0297

NAME OF SUBMITTER:	B. J. Sadoff
Total Attachments: 3 source=assignment-1#page1.tif	
source=assignment-1#page2.tif	
source=assignment-1#page3.tif	

PATENT REEL: 020762 FRAME: 0298

Assignment

U.S. Patent Nos.: 6,613,333; 6,555,114; 6,689,368; 7,101,561; 7,314,925, and U.S. Patent Application Nos.: 08/974,690; 08/635,886; 08/974,685; 09/995,791; 10/128,587; 11/902,807; and 11/381,408

2551-217

# **ASSIGNMENT**

WHEREAS, Innogenetics N.V., (hereinafter ASSIGNOR), Industriepark,
Zwijnaarde 7, Box 4, B-9052, Ghent, BELGIUM and Technologiepark 6, Ghent, Belgium
9052, and having been assigned all right, title and interest in a the following U.S.
Patents and U.S. Patent Applications (hereinafter the Patent Property):

U.S. Patent No.	Issue Date (MM-DD- YYYY)	U.S. Patent Application No.	Application Filing Date (MM-DD- YYYY)	Assignment Recordation Date (MM-DD- YYYY)	Assignment Recordation Reel/Frame
6,613,333	09-02-2003	08/974,690	11-19-1997	04-25-1996	008042/0492
6,555,114	04-29-2003	08/635,886	04-25-1996	04-25-1996	008042/0492
6,689,368	02-10-2004	08/974,685	11-19-1997	04-25-1996	008042/0492
7,101,561	09-05-2006	09/995,791	11-29-2001	07-26-2002	013129/0222
7,314,925	01-01-2008	10/128,587	04-24-2002	11-22-2002	013519/0267
		11/902,807	09-25-2007	12-17-2007	020257/0400
·		11/381,408	05-03-2006	01-06-2005	016128/0422

WHEREAS, ASSIGNOR hereby confirms that ASSIGNOR has the full right to convey all rights, as herein expressed, to the said Patent Property and the inventions embodied therein:

AND WHEREAS, GENimmune, (hereinafter ASSIGNEE), Technologiepark 6, Ghent, Belgium B-9052 is desirous of acquiring all interest therein.

NOW, THEREFORE, in consideration of Ten Euros (€10.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the said ASSIGNOR by the Patent Property hereby sells, assigns, and transfers unto the said ASSIGNEE, its successors, assigns, and legal representatives, the full and

1306333

PATENT

**REEL: 020762 FRAME: 0299** 

NR.941

⊃.3

Assignment

U.S. Patent Nos.: 6,613,333; 6,555,114; 6,689,368; 7,101,561; 7,314,925, and U.S. Patent Application Nos.: 08/974,690; 08/635,886; 08/974,685; 09/995,791; 10/128,587; 11/902,807; and 11/381,408 2551-217

exclusive right to the Patent Property in the United States, including any continuation and divisional applications claiming benefit thereof, together with the right of priority under the International Convention for the Protection of Industrial Property. Inter-American Convention Relating to Patents, Designs and Industrial Models, and any other international agreements to which the United States of America adheres, and hereby authorizes and requests the U.S. Commissioner of Patents and Trademarks to issue Letters Patent to ASSIGNEE, for its interest as ASSIGNEE, its successors, assigns, and legal representatives in said Patent Property.

And, ASSIGNOR hereby agrees to transfer a like interest upon request of said ASSIGNEE, its successors, assigns, and legal representatives, and without further remuneration, in continuation and divisional applications for patents based thereon and claiming benefit thereof; and to execute any papers by ASSIGNEE, its successors, assigns, and legal representatives, deemed essential to ASSIGNEE's full protection and title in and to the inventions hereby transferred and for maintaining any resulting patents concerning said inventions.

I am authorized to execute this ASSIGNMENT on behalf of ASSIGNOR.

Executed this	20th	day of _	March	, 2008.
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			,

Innogenetics N.V.

[SEAL]

- 2 -

1306333

NR.941

P. 4

Assignment

U.S. Patent Nos.: 8,613,333; 6,555,114; 6,689,368; 7,101,561; 7,314,925, and U.S. Patent Application Nos.: 08/974,690; 08/635,886; 08/974,685; 09/995,791; 10/128,587; 11/902,807; and

11/381,408 2551-217

Signature

Ву:

Name: CDW INVEST BYBA

Title: Represented by Christiaan De Wilde

Chief Executive Officer

INNOGENETICS NV

- 3 -

1306333